MedTrace Logo

Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin

NCT02423356 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2018-08-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the heart functioning of patients being treated with with doxorubicin chemotherapy who have sarcoma, lymphoma or breast cancer in order to better predict risk of developing symptomatic heart failure.

Conditions

Interventions

PROCEDURE

Echocardiogram

An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.

Sponsors & Collaborators

  • Daniel Rushing

    lead OTHER

Principal Investigators

  • Daniel A. Rushing, MD · Indiana University (IU) School of Medicine, Department of Medicine; IU Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-23
Primary Completion
2018-02-01
Completion
2018-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02423356 on ClinicalTrials.gov